楚江新材(002171.SZ):國家產業投資基金的持股比例被動稀釋至5%以下
格隆匯9月16日丨楚江新材(002171.SZ)公佈,公司於2020年6月4日公開發行了1830萬張可轉換公司債券(債券簡稱:“楚江轉債”,債券代碼:128109),自2020年12月10日起“楚江轉債”可轉換為公司股份。截至2021年9月15日,“楚江轉債”轉股數量累計為567,373股,公司總股本由實施轉股前的1,333,667,825股增至1,334,235,198股,導致公司持股5%以上股東國家軍民融合產業投資基金有限責任公司(“國家產業投資基金”)持股比例被動稀釋至5%以下。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.